Monitoring Anti-Prostate Cancer Immunity Following Stereotactic Body Radiotherapy (SBRT)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2015 by Mayo Clinic
Information provided by (Responsible Party):
Sean S. Park, Mayo Clinic Identifier:
First received: January 24, 2013
Last updated: June 25, 2015
Last verified: June 2015
Success of cancer immunotherapy is limited by the ability of solid tumors to evade local and systemic antitumoral immune responses. Several mechanisms of tumor immune evasion have been identified, including low intratumor expression of antigens and elevated expression of inhibitory co-regulatory molecules. An effective immunotherapy is one which would induce necrotic cell death and proinflammatory cytokine production. Stereotactic Body Radiotherapy (SBRT) which delivers conformal, tumor-ablating radiation dose may be an effective means of conditioning solid tumors favorable to the initiation of robust antitumoral immune responses.

Oligometastatic Prostate Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Observational Study of Immune Responses in Prostate Cancer Patients Following Stereotactic Body Radiotherapy (SBRT)

Resource links provided by NLM:

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Induction of anti-prostate cancer immunity [ Time Frame: Before, during and after Stereotactic Body Radiotherapy (SBRT) ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA
Whole Blood

Estimated Enrollment: 20
Study Start Date: January 2013
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Oligometastatic Prostate Cancer
Prostate cancer patients with <4 metastatic lesions are eligible to enroll in this observational study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Oligometastatic prostate cancer patients

Inclusion Criteria:

  • Oligometastatic prostate cancer patients with < 4 metastatic lesions that are amenable to Stereotactic Body Radiotherapy (SBRT)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01777802

United States, Minnesota
Mayo Clinic in Rochester Recruiting
Rochester, Minnesota, United States, 55905
Contact: Mary Ann Currie    507-284-4561   
Principal Investigator: Sean S Park, M.D., Ph.D.         
Sub-Investigator: Eugene D Kwon, M.D.         
Sub-Investigator: Haidong Dong, M.D., Ph.D.         
Sub-Investigator: Kenneth R Olivier, M.D.         
Sponsors and Collaborators
Mayo Clinic
Principal Investigator: Sean S Park, MD, PhD Mayo Clinic
  More Information

No publications provided

Responsible Party: Sean S. Park, Assistant Professor, Mayo Clinic Identifier: NCT01777802     History of Changes
Other Study ID Numbers: 12-008383
Study First Received: January 24, 2013
Last Updated: June 25, 2015
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms processed this record on November 25, 2015